US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer
The latest approval was based on the findings from the Phase II DESTINY-Lung02 trial of Enhertu.

The latest approval was based on the findings from the Phase II DESTINY-Lung02 trial of Enhertu.
The darolutamide combination treatment substantially lowered mortality risk by 32.5% in mHSPC patients.
The approval was based on findings from the Phase III DESTINY-Breast04 trial of Enhertu.
The approval was based on the Phase III OlympiA clinical trial of Lynparza versus placebo.
Poseida could get research, development, launch and net sales milestones and other payments totalling up to $6bn.
Non-GAAP diluted EPS dropped 13% to $1.58 in the second quarter of this year.
In a Phase II registrational study in mIDH1 R/R AML patients, olutasidenib showed a strong duration of response.
The company has provided an adjusted diluted EPS guidance range of $13.78 to $13.98 for the full-year 2022.
Thank you for subscribing to Pharmaceutical Technology